CA19-9 Cancer Antigen, Human (Pancreatic, GI or Ovarian Tumor Antigen, Sialyl Lewis a, Carbohydrate Antigen 19-9) BioAssay(TM) ELISA Kit

A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues.\n\nRecently reports indicate that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease. This tumor-associated antigen may also be elevated in some non-malignant conditions. Research studies demonstrate that serum CA 19-9 values may have utility in monitoring subjects with the above-mentioned diagnosed malignancies. \n\nIt has been shown that a persistent elevation in serum CA19-9 value following treatment may be indicative of occult metastatic and/or residual disease. A persistently rising serum CA 19-9 value may be associated with progressive malignant disease and poor therapeutic response. A declining CA 19-9 value may be indicative of a favorable prognosis and good response to treatment.\n\nSample Type:\nSerum\n\nIntended Use:\nFor the quantitative determination of the Cancer Antigen CA19-9 concentration in human serum.\n\nTest Principle:\nThe CA19-9 ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a monoclonal antibody directed against a distinct antigenic determinant on the intact CA19-9 molecule is used for solid phase immobilization (on the microtiter wells). Another CA 19-9 monoclonal antibody conjugated to horseradish peroxidase (HRP) is in the antibody-enzyme conjugate solution. The test sample is allowed to react sequentially with the two antibodies, resulting in the CA19-9 molecules being sandwiched between the solid phase and enzyme-linked antibodies. After two separate incubation steps at\n37 degrees C for 90 minutes, the wells are washed with Wash Buffer to remove unbound labeled antibodies. A solution of TMB Reagent is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of CA19-9 is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450nm.\n\nKit Components:\nMurine monoclonal anti-CA19-9 coated 1x96 well microtiter plate.\nStandard, 0U/ml, 1x1ml \nStandard, 25U/ml, 1x1ml \nStandard, 75U/ml, 1x1ml \nStandard, 150U/ml, 1x1ml \nStandard, 300U/ml, 1x1ml \nStandard, 600U/ml, 1x1ml \nCA 19-9 Assay Buffer, 1x13ml\nEnzyme Conjugate Concentrate (12X), 1x2ml\nCA 19-9 Conjugate Diluent, 1x24ml.\nWash Buffer Concentrate (20X), 1x50ml\nTMB Reagent (One-Step), 1x11ml\nStop Solution (1N HCl), 1x11ml\n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for at least 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C0075-03H

Size

96Tests

References

1 Glenn, J., Steinberg, W.M., Kurtzman, S.H., et at. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 level in patients before and after treatment of carcinoma of the pancreas. J. Clin. Oncol. 1988; 6:462-8. 2 Hayakawa, T., Kondo, T., Shibata, T. et al. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988; 61:1827- 31. 3 Koprowski, H., Herly, M., Steplewski, Z., et al. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212:53-5. 4 Malesci, A., Tommasini, M.A., Bonato, C. et al. Determination of CA19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenteroglogy 1987; 92:60-7.\n5 Safi, F, Roscher, R., Bittner, R., et al. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987; 2:398-403. 6 Steinberg, W. The clinical utility of CA 19-9 tumor associated antigen. American J. of Gastroenterology 1990; 85:350-355. 7 Steinberg, W.M., Gelfand, R., Anderson, K.K., et al. Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90:343-9. 8 Takasaki, H., Uchida, E., Tempero, M.A., et al. Correlative study on expression of CA 19-9 and DU-Pan-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988; 48:1435- 8. 9 Tatsuta, M., Yamamura, H., Iishi H., et al. Values of CA19-9 in the serum, pure pancreatic juice and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985; 56:2669-73. 10 Wang, T.H. Lin, J.W., Chen, D.S., et al. Noninvasive diagnosis of advanced panceatic cancer by real-time ultrasonography, carcinoembryonic antigen, and carbohydrate antigen 19-9. Pancreas 1986; 1:219-23. 11 Strom BL, Maislin G, West SL, et al. Serum CEA and CA19-9: potential future diagnostic or screening tests for gallbladder cancer? Int. J. Cancer 1990; 45:821. 012609.

Alternative Names

Sialyl Lewis (a)